Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
9 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Annovis Bio, Inc.’s names, not what it holds today.
Patents granted
9
9 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 2 in 2024 and 1 in 2023
Applications published
21
6 of them in 2025
Names they are printed under
3
its own name, a former name
By yearGrantedApplications published
'12'13'15'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
ANNOVIS BIO, INC. its own name
US, as the owner printed on each patent
13 publishedQR PHARMA, Inc. a former name
US, as the owner printed on each patent
7 publishedQR PHARMA, INC. a former name
named as the applicant on its applications, in US
1 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Aug 19, 2025 | 12,390,448 | Prevention or of disease states due to metal dis-homeostasis via administration of posiphen to healthy or sick humans | Pharmaceuticals | ANNOVIS BIO, INC. |
| Nov 19, 2024 | 12,144,798 | (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8ahexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration | Pharmaceuticals | ANNOVIS BIO, INC. |
| Jul 23, 2024 | 12,042,482 | Methods of treatment or prevention of acute brain or nerve injuries | Pharmaceuticals | ANNOVIS BIO, INC. |
| Mar 7, 2023 | 11,596,621 | Prevention or treatment of disease states due to metal dis-homeostasis via administration of Posiphen to healthy or sick humans | Pharmaceuticals | ANNOVIS BIO, INC. |
| Aug 2, 2022 | 11,400,075 | (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration | Pharmaceuticals | ANNOVIS BIO, INC. |
| Jul 12, 2022 | 11,382,893 | (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration | Pharmaceuticals | ANNOVIS BIO, INC. |
| Jul 5, 2022 | 11,376,238 | (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration | Pharmaceuticals | ANNOVIS BIO, INC. |
| Aug 24, 2021 | 11,096,926 | (3AR)-1,3A,8-trimethyl-1,2,3,3A,8,8A-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration | Pharmaceuticals | ANNOVIS BIO, INC. |
| Aug 20, 2019 | 10,383,851 | (3aR)-1,3a,8-Trimethyl-1 ,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration | Pharmaceuticals | QR PHARMA, Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Nov 27, 2025 | 2025/0360104 | PREVENTION OR TREATMENT OF DISEASE STATES DUE TO METAL DIS-HOMEOSTASIS | Pharmaceuticals | ANNOVIS BIO, INC. |
| Oct 16, 2025 | 2025/0319068 | TREATMENT OF DISEASES VIA ADMINISTRATION OF BUNTANETAP AND AN ANTIHYPERTENSIVE AGENT | Pharmaceuticals | ANNOVIS BIO, INC. |
| Jul 24, 2025 | 2025/0235429 | TREATMENT OF DISEASES VIA ADMINISTRATION OF BUNTANETAP AND AN ANTIDIABETIC AGENT | Pharmaceuticals | ANNOVIS BIO, INC. |
| Apr 10, 2025 | 2025/0114330 | (3AR)-1,3A,8-TRIMETHYL-1 ,2,3,3A,8,8A-HEXAHYDROPYRROLO[2,3-B]INDOL-5-YL PHENYLCARBAMATE AND METHODS OF TREATING OR PREVENTING NEURODEGENERATION | Pharmaceuticals | ANNOVIS BIO, INC. |
| Jan 23, 2025 | 2025/0025444 | TREATMENT OF NEURODEGENERATIVE DISEASES VIA ADMINISTRATION OF BUNTANETAP AND A PHOSPHODIESTERASE INHIBITOR | Pharmaceuticals | ANNOVIS BIO, INC. |
| Jan 2, 2025 | 2025/0000846 | METHODS OF TREATMENT OR PREVENTION OF ACUTE BRAIN OR NERVE INJURIES | Pharmaceuticals | ANNOVIS BIO, INC. |
| Aug 1, 2024 | 2024/0252467 | TREATMENT OF MENTAL ILLNESS VIA ADMINISTRATION OF BUNTANETAP AND ANALOGUES THEREOF | Pharmaceuticals | ANNOVIS BIO, INC. |
| Nov 9, 2023 | 2023/0355585 | PREVENTION OR TREATMENT OF DISEASE STATES DUE TO METAL DIS-HOMEOSTASIS VIA ADMINISTRATION OF POSIPHEN TO HEALTHY OR SICK HUMANS | Pharmaceuticals | ANNOVIS BIO, INC. · patent 12,390,448 granted from it |
| Nov 24, 2022 | 2022/0370412 | INHIBITION OF NEUROLOGICAL INJURIES DUE TO INFECTIONS VIA ADMINISTRATION OF BUTANETAP AND ANALOGS THEREOF | Pharmaceuticals | ANNOVIS BIO, INC. |
| Oct 13, 2022 | 2022/0323413 | (3AR)-1,3A,8-TRIMETHYL-1 ,2,3,3A,8,8AHEXAHYDROPYRROLO[2,3-B]INDOL-5-YL PHENYLCARBAMATE AND METHODS OF TREATING OR PREVENTING NEURODEGENERATION | Pharmaceuticals | ANNOVIS BIO, INC. · patent 12,144,798 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 7.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.